Cladosporium peptides
AssigneeCircassia Limited
InventorsRoderick Peter Hafner, Paul Laidler, Pascal Hickey, Mark Larche
Life of this patent
Estimating the term…
Abstract
Polypeptides which may be used for preventing or treating allergy to moulds of the Cladosporium and/or Alternaria genus, have up to 30 amino acids in length and comprise: (I) the amino acid sequence: (a) GGYKAAVRPTMLE (SEQ ID NO: 35; Cla35), (b) AE V YQKLK SLTKK (SEQ ID NO: 31; Cla16), (c) VAITYASRAQGAE (SEQ ID NO: 32; Cla25), (d) GHHFKERGT-GSLVIT (SEQ ID NO: 33; Cla26), or (e) ANYTQTKTVSIRL (SEQ ID NO: 34; Cla29); or (II) a T cell epitope-containing variant sequence which is a said amino acid sequence (I) having up to six amino acid modifications, each of which is independently a deletion, substitution or insertion.
Claims28
A method of treating an individual for or preventing in an individual allergy to Cladosporium and/or Alternaria, which method comprises administering to said individual a therapeutically or prophylactically effective amount of (i) a polypeptide, or a pharmaceutically acceptable salt thereof, which is up to 30 amino acids in length and comprises:
- (I) the amino acid sequence:
- (a)
- GGYKAAVRPTMLE,
- (SEQ ID NO:
- 35;
- Cla35)
- (b)
- GHHFKERGTGSLVIT,
- (SEQ ID NO:
- 33;
- Cla26)
- or
- (c)
- ANYTQTKTVSIRL;
- (SEQ ID NO:
- 34;
- Cla29)
- or
- (II) a T cell epitope-containing variant sequence which is a said amino acid sequence (I) having up to three amino acid modifications, wherein the modification is a deletion, substitution or insertion;
- or of
- (ii) a pharmaceutical formulation which comprises a pharmaceutically acceptable carrier or diluent and a polypeptide of (i), or a pharmaceutically acceptable salt thereof.
A method of treating an individual for or preventing in an individual allergy to Cladosporium and/or Alternaria, which method comprises administering to said individual a therapeutically or prophylactically effective amount of
- (i) a polypeptide, or a pharmaceutically acceptable salt thereof, which is up to 30 amino acids in length and comprises:
- (I) the amino acid sequence GGYKAAVRPTMLE (SEQ ID NO:
- 35;
- Cla35), or
- (II) a T cell epitope-containing variant sequence which is a said amino acid sequence (I) having up to three amino acid modifications, wherein the modification is a deletion, substitution or insertion;
- or of
- (ii) a pharmaceutical formulation which comprises a pharmaceutically acceptable carrier or diluent and a polypeptide of (i), or a pharmaceutically acceptable salt thereof.
A method of treating an individual for or preventing in an individual allergy to Cladosporium and/or Alternaria, which method comprises administering to said individual a therapeutically or prophylactically effective amount of
- (i) a polypeptide, or a pharmaceutically acceptable salt thereof, which is up to 30 amino acids in length and comprises:
- (I) the amino acid sequence
- (a)
- GGYKAAVRPTMLE,
- (SEQ ID NO:
- 35;
- Cla35)
- (b)
- GHHFKERGTGSLVIT,
- (SEQ ID NO:
- 33;
- Cla26)
- or
- (c)
- ANYTQTKTVSIRL;
- (SEQ ID NO:
- 34;
- Cla29)
- or
- (II) a variant sequence which is a said amino acid sequence (I) which has one or two amino acid modifications wherein the modification is a deletion or substitution;
- or of (ii) a pharmaceutical formulation which comprises a pharmaceutically acceptable carrier or diluent and a polypeptide of (i), or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.